ReviewWorld journal of clinical oncology2022
Neoadjuvant treatment in non-small cell lung cancer: New perspectives with the incorporation of immunotherapy.
Review in World journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.Nature cancer · 2025Trial
- Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.Cancer science · 2024Trial
- New hybrid pyridine-1,2,4-triazole scaffolds: synthesis, in vitro evaluation of anticancer and antimicrobial activity, and in silico insights.Scientific reports · 2026Article
- Outcomes of robotic anatomic lung resection after neoadjuvant therapy for non-small cell lung cancer.Frontiers in surgery · 2026Article
- The unified front: a multidisciplinary approach in the Era of uniportal thoracic surgery.Frontiers in surgery · 2026Review
- Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer.Oncology letters · 2025Article
- Neoadjuvant chemoimmunotherapy versus chemoradiotherapy for non-small cell lung cancer: a comparative analysis of clinical outcomes and pathologic response.Journal of thoracic disease · 2025Article
- Lower r-FEV1 as a predictor of treatment response and survival in NSCLC patients receiving neoadjuvant immunochemotherapy.Journal of thoracic disease · 2025Article
- Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB-IIIB Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Thoracic cancer · 2025Article
- Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer.Annals of surgical oncology · 2025Review
- Unlocking the potential of immunotherapy for patients with resectable non-small cell lung cancer.Frontiers in oncology · 2025Review
- Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses.Current medicinal chemistry · 2025Review
- Review
- Article
- N1-positive non-small cell lung cancer: surgeons' perspective before undertaking a major resection.Indian journal of thoracic and cardiovascular surgery · 2024Review
- Predicting pathological response to neoadjuvant or conversion chemoimmunotherapy in stage IB-III non-small cell lung cancer patients using radiomic features.Thoracic cancer · 2023Article
- Neoadjuvant immune checkpoint inhibitor treatment + chemotherapy (vs. chemotherapy alone) for locally advanced non‑small cell lung cancer: A retrospective cohort study.Oncology letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of neoadjuvant treatment in non-small cell lung cancer (NSCLC) is to eliminate micrometastatic disease to facilitate surgical resection. Neoadjuvant chemotherapy (ChT) in localised NSCLC has numerous advantages over other therapeutic modalities and is considered standard treatment in resectable disease. Treatment with immune checkpoint inhibitors (ICI) improves long-term survival in advanced disease and has a better toxicity profile than conventional therapies. These immunotherapy agents (anti-PD1/PD-L1), administered with or without ChT, are currently being evaluated in the preoperative setting, with initial results showing better pathological response rates and more long-term benefits. Importantly, these drugs do not appear to increase the rate of severe adverse effects and/or postoperative complications. However, several questions still need to be resolved, including the identification of predictive biomarkers; comparative studies of immunotherapy alone
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.